Metraipolis › archive › dc_acd93d0b2cd0

Impact of PD-1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib-Based Triple Therapy — Europe PMC PMID:42661423

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42661423
DOI
10.1111/liv.70847
License (as archived)
solo-consultazione
Archived
2026-10-07T15:25:09.216Z
SHA-256 of the archived text
57ce547cd6aa492bc8d4246078b9f3b9ace14e041ba50d9bb7d69bad42ac63ae
Stable URL of this page
https://metraipolis.com/documento/dc_acd93d0b2cd0

How to cite

Impact of PD-1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib-Based Triple Therapy — Europe PMC PMID:42661423 — Europe PMC (en), https://europepmc.org/article/MED/42661423 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_acd93d0b2cd0 (Metraipolis archive dc_acd93d0b2cd0, sha256 57ce547cd6aa492bc8d4246078b9f3b9ace14e041ba50d9bb7d69bad42ac63ae)
BibTeX
@misc{dcacd93d0b2cd0,
  title = {Impact of PD-1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib-Based Triple Therapy — Europe PMC PMID:42661423},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42661423},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_acd93d0b2cd0; sha256 57ce547cd6aa492bc8d4246078b9f3b9ace14e041ba50d9bb7d69bad42ac63ae},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42661423. Agents can read the archived copy with the MCP tool read_document.